Peter Alistair Coleman, FCMA MBA
Peter joined Roslin in March 2022, prior to that he was the CEO of Cobra Biologics a position he held from 2011 to Mar 2021 up to when the business was sold.
He has over 20 years of ATMP CDMO experience as both CFO and CEO and he is a qualified accountant with an MBA from Manchester Business School.
He joined Cobra as the CFO on its IPO in 2002, overseeing multiple acquisitions and fundraising activities. During his tenure as CEO of Cobra, he oversaw rapid growth in both revenue and EBITDA as the business focused on Advanced Therapies.
Peter has been an active member of the UK life science infrastructure as a member of the MMIP. He is also a multiple award winner, with the Queen’s Award for Enterprise in 2018 and joint winner of the BIA Richard Wilson Impact Award in 2020 for his involvement in the BIA’s UK COVID Vaccine Taskforce.
Lee Warren, FCA
Lee Warren, FCA
Lee joined RoslinCT as CFO in April 2022, having previously spent over 7 years at Cobra Biologics, most recently as Director, Global Finance. During his time at Cobra Lee oversaw a period of rapid growth and expansion, driving significant revenue and EBITDA growth, and was involved in several M&A transactions.
Lee has an audit background, has spent time in the financial services sector, and subsequently held a number of senior management positions in the mobile telecommunications sector.
Lee is a qualified Chartered Accountant.
Kevin joined the team in 2019 as our Chief Operating Officer. He has more than 20 years working within a regulated scientific environment for small biotech, large CROs and SMEs.
With a background in quality control and engineering, Kevin has held positions in Operations, Quality, R&D and commercial development. He was previously responsible for Roslin Cells’ collaborative projects for the development, GMP translation and manufacture of cell therapies for both pre-clinical and clinical development. More recently, as COO at Censo Biotechnologies, he established the operational capability for the European Bank for Induced Pluripotent Stem Cells and was responsible for Censo’s stem cell generation, genome editing and assay development operations for drug discovery.
Kevin loves playing football and golf, hill walking and spending time with his family and friends!
Alex has over 20 years of experience in Business Development within Biologics/ATMP CDMOs and a proven track record of delivery.
Alex is a Molecular Biologist and has held several roles, including Account Management, Sales and Director of Business Development.
Our Non-Executive Directors
Ian is a pharmacist with 30 years of experience in the Pharmaceutical industry working for GSK, Merck Generics and IVAX. His core capability is in the field of manufacturing and supply chain leadership. He was Chair of the Medicine Manufacturing Industry Partnership (MMIP) between 2013 and 2017 and chaired the Advanced Therapy Manufacturing Task Force to ‘anchor’ commercial-scale manufacturing in the UK. He has been a leading the manufacturing works stream of the UK Government Vaccines Task Force since May 2020 as an industry advisor.
Andrea brings over 30 years’ experience supporting healthcare entrepreneurs, founders, managers and boards develop and grow their businesses globally.
The founder of dedicated European healthcare investment banking franchises at both JP Morgan and Goldman Sachs, Andrea has advised on some of the most significant M&A transactions across leading pharmaceutical, medical device and hospital companies both in Europe and globally. With responsibilities including Vice Chairman of European Investment Banking at JP Morgan and Partner, Managing Director, Head of European Healthcare at Goldman Sachs, Andrea has developed a unique network spanning the entire healthcare value chain and a track record of supporting successful management teams to achieve their growth ambitions through debt and equity financing as well as transactional expertise.
Andrea is currently on the boards of RoslinCT, Envision Pharma Group, FairJourney Biologics, Sterling Pharma, and VISUfarma and has overseen successful exits for Caprion Biosciences.
Originally from Italy and holding a BA in Economics with Highest Honours from the University of North Carolina at Chapel Hill, Andrea has lived and worked across the USA, UK and continental Europe. Andrea helped found a Blueprint for Better Business to help corporates be guided and inspired by a purpose that benefits society.
Alan has over 30 years private equity investment experience, with a strong track record of dedicated healthcare investing.
Previously, Alan was a board member at 3i plc, led the build-out of the 3i Europe office network, and founded 3i’s healthcare sector team as Global Head of Healthcare. Subsequently, Alan was founder, CEO and Chairman of the Investment Committee at Hermes GPE, an active co-investor in private equity-backed healthcare.
Alan is currently a member of the board at RoslinCT, X-Chem, Ardena, Sterling, Linimed and Alcaliber and previously Quotient Sciences until its successful exit.
Alan holds a Bachelor’s degree in Law, an MSc in Enterprise and is a graduate of the Advanced Management Programme at INSEAD. Originally from Scotland, Alan has worked and lived across continental Europe as well as leading deals in North America. He was Chair of the BVCA and for a number of years chaired the BVCA Responsible Investment Advisory Board, and is currently Chairman of the European Healthcare Private Equity Association (eHCPEA).
Geoffrey Hamilton-Fairley is an experienced Chairman, NED and investment advisor with a track record of leading companies at different stages of development from start-ups through to sale and IPO.
His entrepreneurial career started in 1982, founding a number of companies in Public Relations, Technology, Advertising and Music & Personality management backed by The Abingdon Management Company Limited, where he subsequently became sole owner having acquired Abingdon from its institutional shareholders. Abingdon had a number of quoted and unquoted investments including a Unit Trust, Foretronic (a technology company that introduced the magnetic data strip on the back of credit cards), TVS (ITV franchise for the South of England), and a significant property portfolio in the UK and abroad.
Returning to his medical roots, Geoffrey developed and guided Oncimmune, a company pioneering technologies to enable early cancer detection, from a Nottingham University start-up through to a successful IPO in May 2016, with total funds raised of £62m. During this period he co-authored numerous scientific and health economic publications.
He now acts as an advisor to leading technology and healthcare funds, advising investment teams, specific due diligence projects, monitoring investments as a director and mentoring CEOs.
Scientific Advisory Board
Michael Chambers co-founded Aldevron while a North Dakota State University student pursuing degrees in chemistry, microbiology, and biotechnology. Aldevron grew from a small NDSU lab to the leading supplier to the global genomic medicine sector. Today Aldevron manufactures nucleic acids and recombinant enzymes used to make cell and gene therapies, gene editing products, and vaccines. Michael served as Aldevron’s CEO until 2020, when he moved to the Executive Chairman role. Aldevron was sold to Danaher Corporation in 2021 for $9.6 billion and has recently surpassed 750 associates between its Fargo, ND headquarters and Madison, WI site. In addition to Aldevron, Michael is an investor, founder, and board member in technology companies like Calviri, Genovac, Sarepta, and Agathos Bio. He is the primary investor in the apparel company Oliver Cabell and is producing a movie about the 1900 Galveston Hurricane. Michael was named one of the 100 Most Intriguing Entrepreneurs by Goldman Sachs in 2018 and honored as one of the Top 25 Biotech CEOs of 2021 by Healthcare Technology Report. Michael lives with his wife and five daughters, splitting time between Fargo and Boston.
Heidi Hagen has extensive experience in operations management and commercializing innovative technologies from her 30 years in the Biotech industry which includes 20 years in the Cell and Gene Therapy industry. Currently, Heidi is Chief Technology Officer of Sonoma Biotherapeutics, a privately held company leading the development of adoptive Treg cell therapies for autoimmune and inflammatory diseases. She also serves on the Board of Directors for a public, cell therapy commercial company, Vericel Inc. Previously she served on the board at Ziopharm Oncology Inc. (now called Alaunos Inc.), and as interim CEO, a publicly traded company developing immune-oncology gene and cell therapies. Prior to Ziopharm she was a co-founder of Vineti, a software platform company for cell and gene therapy supply chain management and served as Global COO for SOTIO Biotech a.s.. As the Senior Vice President of Operations for Dendreon for 10 years and she was responsible for the buildout of the operations for the first Active Cellular Immunotherapy (ACI), Provenge. She began her career at Immunex Corporation over ten years in a range of roles in drug development and operations management. Heidi has a B.S. in Cell and Molecular Biology, an M.S. in Bioengineering, and an MBA from the University of Washington.
Margit Jeschke, Ph.D.
Dr. Margit Jeschke was leading the global Analytical Stewardship & CMC Product Sciences section within Novartis Cell & Gene Technical Development & Manufacturing before she started working as an independent consultant in January 2022.
In her previous position, she was responsible for the analytical development strategy of the company’s Cell & Gene Therapy products including overall product control strategy, specification setting, comparability studies, as well as CMC correlational sciences. Margit joined the newly formed CGT organization in 2012 after holding several positions of increasing responsibility within Novartis Biopharmaceutical Development including leading Analytical Research & Development of Novartis Biologics in Basel. She served two years in New Jersey building up and leading the CGT Technical Development unit co-located at the manufacturing plant in Morris Plains enabling manufacturing and commercialization of CTL019/Kymriah and was responsible for the analytical content in the registration dossier of the first CAR T product receiving FDA approval.
Margit holds a Ph.D. in Biochemistry from the University of Basel, Switzerland.
Michael Kalos, Ph.D.
Dr. Michael Kalos is an internationally recognized expert in T cell therapy and immunotherapy and brings over 25 years of experience and expertise in cell therapy, oncology vaccines, and immunooncology.
Michael is currently Founder and Managing Director at Next Pillar Consulting, an LLC focused on providing consulting and advising services in the biopharmaceutical and venture space. Prior to his consulting venture, Michael served as Executive Vice President and Head of R&D at ArsenalBio, a synthetic biology-based cell therapy start-up. At ArsenalBio Michael led the development of R&D and product development strategy for the company’s first product. Prior to ArsenalBio Michael served as Vice President of Immunooncology and Oncology Cell Therapies at Janssen, the pharmaceutical companies of Johnson and Johnson, where he led corporate internal and external strategy and efforts in cell therapy, neoantigen vaccines, and immunooncology. Prior to Janssen, Michael served as Chief Scientific Officer of immunooncology at Eli Lilly and Company, where he established and led internal and external corporate strategy in immunooncology, including biologics, bi-specifics, vaccines, and cell therapy. Prior to joining the biopharmaceutical sector, Michael spent 10 years in academia, where he focused on the development of integrated translational biomarker programs to support the development of cell therapy and immunotherapy programs. The laboratory he founded and directed at the University of Pennsylvania played a key role in the success of the cell therapy program at Penn, including clinical development of the CTL019 program that was licensed to Novartis and led to the approval of Kymriah.
Michael obtained his Ph.D. from the University of Minnesota and completed post-doctoral training in the laboratory of Phil Greenberg at the Fred Hutchinson Cancer Research Center.
Michael has co-authored over 85 peer-reviewed manuscripts, including multiple highly cited articles in high-impact journals that have helped define the space of CAR- and TCR- based T cell therapy, as well as book chapters in the field of cancer immunotherapy, and has 26 issued patents in the field of cell therapy, immunotherapy, and vaccines. He actively serves as a board and advisory member for biopharmaceutical companies as well as international immunotherapy consortia and societies.
Michael Mendicino, Ph.D
Michael Mendicino, Ph.D. is a multi-disciplinary cell & gene therapy subject matter expert with over 24 years of experience, educated in molecular/cellular biology/genetics, immunology, and regulatory science. Michael founded Hybrid Concepts International (HCI) as a consultancy and advisory firm and is President/Owner, and Chief Consultant & Advisor. HCI is a niche firm in exponentially growing fields of cell therapy, gene and gene-modified cell therapies, other regenerative medicines, tissue engineering, and cell-based drug discovery that has successfully served over 125 clients since its establishment. Michael manages over nearly 20 experts under the HCI umbrella. Michael previously worked at numerous biotech companies, and/or consulted, all within the aforementioned fields, covering areas such as CMC, strategic regulatory affairs, regulatory meetings & submissions, R & D, commercial, and product & technology due diligence activities. His experience ranges from early preclinical to post-regulatory approval, working with private and public companies, contract manufacturers, and investors, in the aforementioned areas, as well as multi-disciplinary early-stage start-up/stealth support (e.g., EVP, Dept. Head, C-level advisory roles). During his prior FDA appointment, Michael worked primarily in what is now the Office of Tissues & Advanced Therapies (OTAT), where he performed regulatory submission review, and special projects, and provided guidance to sponsors for OTAT-regulated products, and devices, including combination products. Michael is a representative on multiple Alliance for Regenerative Medicine (ARM) Committees (current Co-Chair of CMC Regulatory Task Force), and International Society for Cellular Therapy (ISCT) committees. Also, Michael is a Co-founder and on the Board of Directors for the Standards Coordinating Body (SCB). Michael has published FDA-related articles in Nature Biotechnology and Cell Stem Cell, and recently led authoring of landmark regulatory review publications and book chapters.
Consulting firm website: https://www.OurHybridConcepts.com/.
“I joined RoslinCT at a really exciting time during the company’s growth, and it is so exciting to see all the vacancies we have planned for the next few years. The work we do is cutting edge and so inspiring and it is an honour to be involved in a company with such an impressive portfolio of services and such talented, driven and lovely staff.”
“I have been part of the RoslinCT team for a year and a half now and I have enjoyed every minute of it. RoslinCT instils a warm culture where there is mutual respect for one another and great opportunity for growth. I feel privileged to work in such a challenging and positive work environment where the focus is on delivering life-changing therapies for patients across the globe.”